US 12,458,680 B2
Reconstitutable teverelix-TFA composition
Finn Larsen, Hawick (GB); Francois Boutignon, Clermont-Ferrand (FR); and Guy Poland, Bristol (GB)
Assigned to Antev Limited, London (GB)
Filed by Antev Limited, London (GB)
Filed on Mar. 17, 2023, as Appl. No. 18/122,991.
Application 18/122,991 is a continuation of application No. 17/254,859, granted, now 11,633,453, previously published as PCT/EP2019/067718, filed on Jul. 2, 2019.
Claims priority of application No. 18181931 (EP), filed on Jul. 5, 2018.
Prior Publication US 2023/0285503 A1, Sep. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/09 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/12 (2006.01)
CPC A61K 38/09 (2013.01) [A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 47/12 (2013.01)] 10 Claims
 
1. A method of preparing a reconstitutable teverelix-trifluoroacetate (TFA) composition, wherein said method comprises
mixing teverelix and trifluoroacetate at a molar ratio of between 1:1.3 and 1:1.6, as determined by measuring a content of trifluoroacetate and teverelix in an aqueous teverelix-TFA solution using an HPLC method, thereby providing the aqueous teverelix-TFA solution without any microcrystals, and
drying the aqueous teverelix-TFA solution.